Plus Therapeutics Inc (PSTV) - News Archive

Plus Therapeutics Secures $15 Million in Private Placement Funding Amid Share Repurchase ProgramIn a significant development for Plus Therapeutics, Inc. the clinical-stage pharmaceutical company focused on developing ta...

In an evolving landscape of biopharmaceutical innovation, Plus Therapeutics Inc. is gripping attention, particularly with the recent appointment of new leadership within its CNSide Diagnostics subsidiary. This strategic...

At the recently concluded Society for Neuro-Oncology (SNO) Annual Conference in 2024, Plus Therapeutics presented compelling interim data from its ReSPECT-LM Phase 1 trial, examining the efficacy of Rhenium-186 nanoLipo...

Revolutionizing Cancer Treatment: Plus Therapeutics Groundbreaking Advances in CNSide Assays and ReSPECT Clinical Trials for CNS Metastases Plus Therapeutics is pushing the frontiers of oncology with its latest research...

Unlocking New Horizons in Neuro-Oncology: Plus Therapeutics Pioneering Advances in Leptomeningeal Metastases and Glioblastoma MultiformePlus Therapeutics is making notable strides in the realm of neuro-oncology, showcas...

In a significant development for the biopharmaceutical sector, Plus Therapeutics Inc. (NASDAQ: PSTV) has announced a strategic manufacturing partnership with SpectronRx, focused on advancing their radiotherapeutic produ...

News Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting In a pivotal presentation at the 2024 Congress of Neurological Surgeons Annual Meeting, Plus...

In the luminescent halls of progress, where the realms of medicine and fortitude converge, a bastion of hope doth arise in the form of Plus Therapeutics Inc. This month, amidst the cacophony of economic fluctuations tha...

Leptomeningeal metastases (LM) represent a significant challenge in oncology, often impacting prognosis and treatment outcomes. Recent presentations at the 2024 Society for Neuro-Oncology (SNO) and American Society of C...

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of CancerPlus Therapeutics, a leading pharmaceutical company focused on developing innovative therapies for the...

In a time of economic uncertainty, Plus Therapeutics Inc. has managed to defy market trends by strengthening its financial position in the third quarter of 2023. Despite a net increase in borrowings by -7.67%, the compa...

Plus Therapeutics, an oncology-focused pharmaceutical company, recently provided updates on two major fronts its Leptomeningeal Metastases acquisition and topline data from The Foresee (186Re) trial. Leptomeningeal meta...

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense and Improves Total Debt to Equity RatioPlus Therapeutics Inc. has recently received a $3 million award recommendati...

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus Management TeamThe healthcare industry is constantly evolving and advancing, and it is essential for companies to have access to experts in...

The diagnosis and treatment of leptomeningeal metastasis, a devastating complication of adenocarcinoma and melanoma, is often challenging due to the limited tools available for accurate identification of cancer cells in...

Plus Therapeutics, a leading pharmaceutical company, has successfully achieved a significant milestone in its groundbreaking clinical trial investigating the efficacy of Rhenium (186Re) Obisbemeda for the treatment of L...

In a groundbreaking collaboration, Plus Therapeutics has joined forces with K2bio to develop innovative tests for the analysis of cerebrospinal fluid (CSF) tumor cells and molecular biomarkers. This partnership aims to...

Plus Therapeutics, Inc. (Nasdaq: PSTV), a leading clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, has announced its Board of Directors approval of a c...